Open an account

CEL-SCI

CVM · NYSE American

$1.55−$0.10 (−6.06%)TodayMarket closed ·
Prev close $1.65

About CVM

CEL-SCI Corp. is a clinical-stage biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The company is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. The company is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).

Employees
0
Headquarters
Vienna, Virginia
Listed
Dec 8, 1983
Sector
Health Care
Industry
Biotechnology
Website
cel-sci.com

CVM key statistics

Market cap
27.26M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
294.78K
Volume
140.47K
Open price
$1.65
High today
$1.66
Low today
$1.54
52 Week high
$9.35
52 Week low
$0.89

CEL-SCI (CVM) at a glance

As of Oct 20, 2026, CEL-SCI (CVM) shares are priced at $1.55, giving the company a market cap of 27.26M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $1.54 and $1.66. The current price is 0.6% above the day's low and 6.7% below its high.

Volume so far is 140.47K shares, below the average of 294.78K shares a day.

Over the past year CEL-SCI has ranged from $0.89 to $9.35, and now sits 8% of the way up that range.

CEL-SCI met or beat analyst EPS estimates in 4 of the last 8 quarters. In Q4 FY24 it reported -$2.70 per share against an estimate of -$3.33.

CVM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 4 of the last 8 quarters, by 9.0% on average.

  1. Q4 FY22: reported -$6.30 per share against an estimate of -$6.06
  2. Q1 FY23: reported -$5.40 per share against an estimate of -$6.36
  3. Q2 FY23: reported -$5.70 per share against an estimate of -$5.15
  4. Q3 FY23: reported -$5.67 per share against an estimate of -$4.85
  5. Q4 FY23: reported -$4.80 per share against an estimate of -$4.85
  6. Q2 FY24: reported -$4.20 per share against an estimate of -$4.24
  7. Q3 FY24: reported -$4.20 per share against an estimate of -$3.94
  8. Q4 FY24: reported -$2.70 per share against an estimate of -$3.33

CVM news

  • Press releaseBusiness Wire

    CEL-SCI Invited to Deliver Keynote Address on Multikine at 6th World Congress on Otology, Rhinology and Laryngology

  • Press releaseBusiness Wire

    CEL-SCI Reports Fiscal Third Quarter 2026 Results

  • Press releaseBusiness Wire

    CEL-SCI Study Published in Peer-Reviewed Oral Oncology Supports Multikine's Biomarker Strategy and Potential Overall Survival Benefit Ahead of Head and Neck Cancer Confirmatory Registration Study

  • Press releaseBusiness Wire

    Leading Oncology Journal Accepts For Publication New CEL-SCI Multikine Phase 3 Data Demonstrating Overall Survival Benefit in Underserved Head and Neck Cancer Patients

  • Press releaseBusiness Wire

    CEL-SCI to Launch FDA Registration-Enabling Phase 3 Confirmatory Study to Bring Multikine® to Market for Newly Diagnosed Head and Neck Cancer

  • Press releaseBusiness Wire

    CEL-SCI and Saudi Amarox Hold Strategic Agreement Signing Ceremony at BIO 2026, Advancing U.S.–Saudi Cooperation in Cancer Care

  • Press releaseBusiness Wire

    CEL-SCI Announces Closing of Offering

  • Press releaseBusiness Wire

    CEL-SCI Advances Multikine® Immunotherapy for Head and Neck Cancer Through Dual U.S. Registration Study and Saudi Market Entry Strategy

Similar companies

Companies in the same industry as CEL-SCI

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.